

Monday 28<sup>th</sup> September,

Dear FSGA Members,

**RE: Important Update Regarding Fabrazyme®**

Genzyme Australasia Pty Ltd made contact with me on Friday 25<sup>th</sup> September with an update regarding the current Fabrazyme supply. Please see attached letter from Katy Williams Day Director Regulatory and Scientific Affairs for Genzyme Australasia Pty Ltd.

As many of you are aware by now, there has been disruption in the supply of the Genzyme Fabry treatment product Fabrazyme. Genzyme detected a virus that impairs cell growth in one of six bioreactors at its Allston Landing manufacturing facility in the U.S. The company has decided to temporarily interrupt bulk production at the plant to sanitise the facility.

Current inventories for Cerezyme® (Gaucher treatment drug) and Fabrazyme® (Fabry Disease treatment drug) are not sufficient to meet projected global demand.

The Fabrazyme supply constraints were expected to occur for a limited period. However the constraints will unfortunately be extending until the end of the year. Genzyme presently have sufficient Fabrazyme to supply 30% of global demand for the period of 1 October 2009 through to the end of 2009.

The proactive dose rationing strategies implemented by the Life Saving Drugs Program (LSDP) in August 2009 will be continued until notification that adequate supply has been restored.

Genzyme anticipates this to be resolved by the end of 2009.

To remain updated with current information about Fabrazyme supply issues please visit [www.genzyme.com](http://www.genzyme.com) and [www.genzyme.com/supplyupdate](http://www.genzyme.com/supplyupdate).

I hope this helps keep you up to date.

For more information or to discuss any concerns, please contact the LSDP at (02) 6289 8003 or [lsdp@health.gov.au](mailto:lsdp@health.gov.au).

Kind Regards

Megan Fookes  
President  
Fabry Support Group Australia Inc

